Results 141 to 150 of about 19,040 (169)

Heparin-induced Thrombocytopenia

Haemostasis, 2009
Heparin-induced thrombocytopenia is the most frequent and the most important idiosyncratic haematological drug reaction. It is important for several reasons: first, because heparin is used so often, and the frequency of heparin-induced thrombocytopenia is high, the risk of a hospitalized patient developing heparin-induced thrombocytopenia is high ...
openaire   +2 more sources

Heparin-Induced Thrombocytopenia

Surgical Clinics of North America, 2012
This article deals with heparin-induced thrombocytopenia. It discusses the pathophysiology of the disease, as well as the diagnostic challenges and therapeutic management. The incidence of the disease and screening recommendations are reviewed. The article also emphasizes the importance of correct diagnosis and treatment options.
Stephen, Lanzarotti, John A, Weigelt
openaire   +2 more sources

Heparin-induced thrombocytopenia

Current Treatment Options in Cardiovascular Medicine, 2001
Treatment with heparin is associated with two types of thrombocytopenia. The most worrisome of these is the immune-mediated heparin-induced thrombocytopenia (HIT type II). Suspicion of HIT type II mandates immediate cessation of heparin administration and consideration of an alternative anticoagulation therapy.
openaire   +2 more sources

Hirudin in Heparin-Induced Thrombocytopenia

Seminars in Thrombosis and Hemostasis, 2002
Heparin-induced thrombocytopenia (HIT), a serious side effect of heparin treatment, requires alternative anticoagulation in most affected patients. The recombinant hirudin (r-hirudin) lepirudin has been approved for this purpose after two prospective trials in laboratory-confirmed HIT patients.
Norbert, Lubenow, Andreas, Greinacher
openaire   +2 more sources

Heparin-Induced Immune Thrombocytopenia

New England Journal of Medicine, 1976
We studied five patients in whom severe thrombocytopenia developed during intermittent intravenous heparin treatment of arterial and venous thrombosis. Platelet aggregation was demonstrated when heparin (0.5 U per milliliter) was incubated with the patients' citrated platelet-rich plasma or with normal platelet-rich plasma in the presence of the ...
R B, Babcock, C W, Dumper, W B, Scharfman   +2 more
openaire   +2 more sources

Heparin-Induced Thrombocytopenia

JAMA: The Journal of the American Medical Association, 1979
Heparin, a drug responsible for a majority of drug deaths in patients who are reasonably healthy,1still eludes precise definition as to its structural composition.2Derived from mast cells of bovine lung and porcine gut, heparin preparations may vary in purity and antigenic effects.
openaire   +2 more sources

Pharmacotherapy of heparin-induced thrombocytopenia

Expert Opinion on Pharmacotherapy, 2003
Heparin-induced thrombocytopenia (HIT) is a life-and-limb threatening condition that is associated with the development of antibodies that activate platelets and the coagulation system in the presence of unfractionated heparin or low molecular weight heparin. The binding of antibody to heparin-PF-4 complexes can activate platelets, leading to an acute,
William E, Dager, Richard H, White
openaire   +2 more sources

Heparin-induced thrombocytopenia

The Annals of Thoracic Surgery, 1993
D, Ouellette, A H, Menkis
openaire   +2 more sources

Heparin-Induced Thrombocytopenia

Kardiologiia
The extensive use of therapeutic doses of heparin to prevent thrombosis in critically ill patients with COVID-19 during the pandemic has led to an increased incidence of bleeding and heparin-induced thrombocytopenia (HIT). In addition, the introduction of the AstraZeneca and Johnson&Johnson vaccines against COVID-19 into clinical practice was ...
openaire   +2 more sources

Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management

Vascular Medicine, 2020
Jeffrey S Berger, Marie Hogan
exaly